Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 6/20 | 0.70 |
| ▸ | CYP1B1 | Q16678 | 6/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.70 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.70 |
| ▸ | JUN | P05412 | 1/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.64 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | HMGCR | P04035 | 1/20 | 0.59 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.58 |
| ▸ | PDE4A | P27815 | 1/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.55 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7871043 | 1.00 | CYP1A1 (0.70) | CYP1A1CYP1B1CYP1A2NFE2L2JUN | |
| SCHEMBL14224730 | 1.00 | CYP1A1 (0.70) | CYP1A1CYP1B1CYP1A2NFE2L2JUN | |
| SCHEMBL30474601 | 1.00 | CYP1A1 (0.70) | CYP1A1CYP1B1CYP1A2NFE2L2JUN | |
| SCHEMBL15932971 | 0.87 | CYP1A1 (0.69) | CYP1A1CYP1B1CYP1A2NFE2L2JUN | |
| SCHEMBL11874692 | 0.86 | CYP1A1 (0.79) | CYP1A1CYP1B1CYP1A2NFE2L2JUN | |
| SCHEMBL11874684 | 0.86 | CYP1A1 (0.79) | CYP1A1CYP1B1CYP1A2NFE2L2JUN | |
| SCHEMBL12090696 | 0.84 | CYP1A2 (0.81) | CYP1A1CYP1B1CYP1A2NFE2L2CYP19A1 | |
| SCHEMBL3172829 | 0.84 | CYP1A2 (0.81) | CYP1A1CYP1B1CYP1A2NFE2L2CYP19A1 | |
| SCHEMBL3172823 | 0.84 | CYP1A2 (0.81) | CYP1A1CYP1B1CYP1A2NFE2L2CYP19A1 | |
| SCHEMBL20160810 | 0.84 | CYP1A1 (0.51) | CYP1A1CYP1B1CYP1A2NFE2L2JUN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3225616-A1 | ALPHA-ASARY-LALDEHYDE ESTER, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Northwest University (CN) | 2017-10-04 | — | — | EP | disclosed |
| US-20170260122-A1 | a-ASARY-LALDEHYDE ESTER, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | NORTHWEST UNIVERSITY (CN) | 2017-09-14 | — | — | US | disclosed |
| US-9035287-B2 | Polymeric materials for use in metal-oxide-semiconductor field-effect transistors | POLYERA CORPORATION (US) | 2015-05-19 | — | — | US | disclosed |
| US-8895497-B2 | Cathepsin S inhibitors | DCB-USA, LLC (US) | 2014-11-25 | — | — | US | disclosed |
| US-20140217395-A1 | Polymeric Materials for Use in Metal-Oxide-Semiconductor Field-Effect Transistors | POLYERA CORPORATION (US) | 2014-08-07 | — | — | US | disclosed |
| US-8629126-B2 | Quinolone derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC. (JP) | 2014-01-14 | — | — | US | disclosed |
| US-20120136025-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2012-05-31 | — | — | US | disclosed |
| EP-2036955-B1 | DYESTUFF, DYE-SENSITIZED SOLAR CELL, AND METHOD FOR MANUFACTURING SAME | JSR CORP (JP) | 2012-05-16 | — | — | EP | disclosed |
| US-8133882-B2 | Quinolone derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC (JP) | 2012-03-13 | — | — | US | disclosed |
| US-8133882-B2 | Quinolone derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC (JP) | 2012-03-13 | — | — | US | disclosed |
| EP-1995240-B1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2012-02-22 | — | — | EP | disclosed |
| WO-2011069149-A2 | CATHEPSIN S INHIBITORS | DCB-USA LLC (US) | 2011-06-09 | — | — | WO | disclosed |
| US-20090197834-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-08-06 | — | — | US | disclosed |
| US-20090197834-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-08-06 | — | — | US | disclosed |
| EP-2036955-A1 | Dyestuff, dye-sensitized solar cell, and method for manufacturing same | JSR Corporation (JP) | 2009-03-18 | — | — | EP | disclosed |
| EP-1995240-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120136025-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | P2RY10, P2RY12, P2RY11 | CYP1A1 1894/4885CYP1B1 1284/4885CYP1A2 1317/4885 |
| US-20170260122-A1 | a-ASARY-LALDEHYDE ESTER, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | LSS, CYP51A1, BACE1 | CYP1A1 638/4885CYP1B1 607/4885CYP1A2 531/4885 |
| US-20090197834-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | P2RY12, P2RY11, P2RY10 | CYP1A1 2786/4885CYP1B1 1732/4885CYP1A2 2147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.